TNF and psoriasis vulgaris: The present study aims to evaluate the incidence of new-onset PsA in patients with plaque psoriasis on anti-TNFα (adalimumab, certolizumab, etanercept, infliximab), anti-IL12/23 (ustekinumab), anti-IL23 (risankizumab, tildrakizumab, guselkumab) or anti-IL17 (brodalumab, ixekizumab, secukinumab) therapy attending our Dermatology Unit and undergoing at least 1-year follow-up.